What is the pathophysiology of pneumonia in infants and young children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Pathophysiology of Pediatric Pneumonia

Pediatric pneumonia results from infection of the lung parenchyma by pathogens that vary predictably by age, with younger children predominantly affected by viral invasion of small airways causing obstruction and atelectasis, while older children experience bacterial alveolar consolidation, most commonly from Streptococcus pneumoniae. 1, 2

Age-Dependent Pathophysiologic Mechanisms

Infants and Young Children (<5 years)

The peripheral airways of infants are anatomically more susceptible to inflammatory narrowing than adults, making small airway obstruction the primary pathophysiologic mechanism rather than alveolar consolidation. 3

  • Viral pathogens (14-35% of cases) cause bronchiolar inflammation leading to airway obstruction, air-trapping, and atelectasis rather than true consolidative pneumonia. 1, 3
  • Respiratory syncytial virus (RSV) is the predominant viral pathogen, causing bronchiolar epithelial damage and mucus plugging. 1
  • The resulting airway obstruction manifests radiographically as generalized hyperinflation and irregular aeration patterns. 3
  • This small airway obstruction frequently causes severe respiratory embarrassment disproportionate to the degree of parenchymal involvement. 3

School-Aged Children and Adolescents (≥5 years)

Older children develop classic bacterial pneumonia with alveolar consolidation, following a pathophysiologic pattern more similar to adults. 1

  • Streptococcus pneumoniae (16-37% when serologic testing is used) causes alveolar filling with inflammatory exudate and consolidation. 1
  • Mycoplasma pneumoniae (4-39% of cases) and Chlamydia pneumoniae (0-20%) cause interstitial inflammation with a slowly progressive course over 3-5 days. 1, 4
  • These atypical pathogens produce less severe alveolar consolidation with more prominent interstitial involvement. 4

Pathogen-Specific Mechanisms

Bacterial Pneumonia

Streptococcus pneumoniae remains the most common bacterial cause across all pediatric age groups, causing acute alveolar inflammation and consolidation. 1, 2

  • Pneumococcal invasion triggers acute inflammatory response with neutrophil recruitment and alveolar exudate formation. 1
  • Staphylococcus aureus (particularly in infants <6 months) causes necrotizing pneumonia with tissue destruction and frequent ICU admission. 5, 2
  • Haemophilus influenzae type b is now rare in appropriately immunized children. 2

Atypical Bacterial Pneumonia

Mycoplasma pneumoniae causes slowly progressive interstitial inflammation beginning with upper respiratory symptoms before descending to the lower airways. 4, 6

  • The pathophysiology involves attachment to respiratory epithelium without tissue invasion, causing ciliary dysfunction and inflammatory response. 4, 6
  • This produces the characteristic slowly progressive illness over 3-5 days with malaise, sore throat, low-grade fever, and eventually cough. 4
  • Wheezing occurs in approximately 30% of cases due to bronchial inflammation and hyperreactivity. 4, 6

Viral Pneumonia

Viral pathogens cause direct epithelial cell damage and inflammatory response in bronchioles and alveoli, with RSV being the predominant pathogen in young children. 1

  • Viral invasion causes epithelial necrosis, increased mucus production, and bronchiolar obstruction. 3
  • Secondary bacterial infection occurs in 8-40% of cases, representing mixed viral-bacterial pathophysiology. 1, 2

Mixed Infections

A significant proportion (8-40%) of pediatric pneumonia cases involve co-infection with multiple pathogens, complicating the pathophysiologic picture. 1, 2

  • Mixed viral-bacterial infections occur in 30% of cases, with dual viral infections in 13% and dual bacterial infections in 7%. 1
  • Co-infection typically involves viral disruption of epithelial barriers facilitating secondary bacterial invasion. 1

Clinical Implications of Pathophysiology

Severity Determinants

Young age (<6 months) is an independent risk factor for severe disease due to anatomically smaller airways and immature immune responses. 5

  • Attack rates are highest in infants (35-40 per 1000) compared to school-aged children (15 per 1000). 5
  • Infants have greater risk of respiratory failure requiring mechanical ventilation due to small airway obstruction. 5, 3

Complications

The pathophysiology can progress to necrotizing pneumonia (particularly with CA-MRSA), pleural effusion/empyema, or respiratory failure requiring ICU admission. 5

  • Panton-Valentine leukocidin-positive S. aureus causes tissue necrosis with 78% requiring mechanical ventilation. 5
  • Impending respiratory failure manifests as sustained tachycardia, inadequate blood pressure, or oxygen saturation ≤92% on FiO2 ≥0.50. 5

References

2
Guideline

Common Infections in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3
Research

Lower respiratory infections: how infants differ from adults.

Radiologic clinics of North America, 1978

4
Guideline

Mycoplasma Pneumonia Clinical Presentation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

6
Guideline

Mycoplasma Pneumonia Diagnosis and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the diagnostic approach for bronchopneumonia in pediatric patients?
How should I manage an adult patient on lactated Ringer's who is developing worsening hyperchloremia and non‑anion‑gap metabolic acidosis?
When should venetoclax be initiated relative to the treatment cycles of acalabrutinib (Calquence) 100 mg twice daily or zanubrutinib (Brukinsa) 160 mg twice daily in a patient without significant cardiac arrhythmia or hepatic impairment?
What are spondyloarthritis (SPA) and diffuse idiopathic skeletal hyperostosis (DISH)?
My cervical MRI revealed a syrinx; what is a cervical syrinx?
Is sublingual clonidine indicated for treating hypertensive urgency (blood pressure ≥180/110 mm Hg without evidence of acute target‑organ damage)?
What could cause a bitter or metallic taste in a patient taking oral antidiabetic medication, and how should it be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.